Sort
17,288 grants matching “multiple sclerosis”
Accelerated Discovery and Development of New Pain Therapeutics
$198,960Lillian W Chiang · Aestus Therapeutics, Inc. · R43 · FY2007 · NS
Dissecting the Heterogeneous Molecular Mechanisms Underlying Multiple Sclerosis Progression
$198,928Ahmed Abdelhak · University Of California, San Francisco · K23 · FY2025 · NS
Alpha9*-Nicotinic Receptors in Autoimmunity and Inflammation
$198,779Ronald J Lukas · St. Joseph'S Hospital And Medical Center · R21 · FY2014 · NS
Autoimmune responses associated with SARS-CoV-2 infection
$198,750Sarah E. Wheeler · University Of Pittsburgh At Pittsburgh · R21 · FY2023 · AI
Characterization of Gastric Evoked Potentials
$198,750David J Levinthal · University Of Pittsburgh At Pittsburgh · R21 · FY2023 · NS
Association between altered gut microbiota and the pathogenesis of Multiple Sclerosis
$198,750Kouichi Ito · Rbhs-Robert Wood Johnson Medical School · R21 · FY2018 · AI
Genetic ancestry differences in IgE- mediated peanut allergy in African Americans
$198,750Tesfaye B. Mersha · Cincinnati Childrens Hosp Med Ctr · R21 · FY2021 · AI
Immune Contribution to Brain Atrophy
$198,750Aaron J Johnson · Mayo Clinic Rochester · R21 · FY2017 · NS
Understanding the impact of AAK1 on T cell chemokine receptor expression and chemotaxis
$198,750Laura Marie Rogers · Mayo Clinic Rochester · R21 · FY2022 · AI
Studying microglial function using cell ablation approaches
$198,750Long-Jun Wu · Mayo Clinic Rochester · R21 · FY2017 · DE
ROLE OF IL-23 IN PSORIASIS PATHOGENESIS
$198,660Andrew Blauvelt · Oregon Health & Science University · R21 · FY2007 · AR
Role of Innate Immunity in EAE
$198,656Robert H Swanborg · Wayne State University · R01 · FY2007 · NS
Genetic Modifiers of MHC Class II Presentation in Autoimmune Diabetes
$198,600Stephan Kissler · Joslin Diabetes Center · R56 · FY2016 · DK
Antibody Mediated Autoimmunity in Neuromyelitis Optica
$198,585Hans-Christian Von Buedingen · University Of California, San Francisco · K02 · FY2012 · NS
Antibody Mediated Autoimmunity in Neuromyelitis Optica
$198,585Hans-Christian Von Buedingen · University Of California, San Francisco · K02 · FY2013 · NS
Novel Therapy for Multiple Sclerosis (SBIR-Phase II)
$198,514Feng-Qiao Li · Cognosci, Inc. · R44 · FY2008 · NS
Investigating the role of cerebral perfusion in demyelination and repair in multiple sclerosis with MRI
$198,494Ashley M Stokes · St. Joseph'S Hospital And Medical Center · R21 · FY2023 · NS
Measuring Sensitivity to Nonignorability
$198,406Columbia University Health Sciences · R01 · FY2001 · HL
Identification of plasma hydroxysphingolipids as biomarkers of demyelination and neurodegeneration underlying physical function decline in older adults
$198,334Danni Li · University Of Minnesota · R21 · FY2019 · AG
Regulation of Neuromyelitis Optica via Tolerance Induced by PLG Nanoparticles Encapsulating Aquaporin 4 Epitopes
$198,333Stephen D Miller · Northwestern University At Chicago · R21 · FY2021 · AI
Post-mortem MRI for improving the diagnosis of Alzheimerâs mimics in the oldest old
$198,301Seyed Ahmad Sajjadi · University Of California-Irvine · R21 · FY2023 · AG
Core D
$198,275Leonard Petrucelli · Mayo Clinic Jacksonville · P01 · FY2022 · NS
Changes in hippocampal microstructure and hippocampal-dependent memory accompanying hormonal fluctuation in naturally cycling women
$198,250Hillary Schwarb · University Of Illinois At Urbana-Champaign · R21 · FY2023 · MH
Prediction of risk of disability worsening and inflammatory disease activity in MS utilizing multimodal prediction algorithms
$198,132Elias S Sotirchos · Johns Hopkins University · K23 · FY2023 · NS
Visual Dysfunction and Quality of Life in MS
$198,125University Of Pennsylvania · R01 · FY2001 · EY